Part B Step Therapy Drug List

Effective July 1, 2020

The Centers for Medicare and Medicaid Services (CMS) now allows Medicare Advantage (MA) plans to apply step therapy for physician-administered and other Part B drugs. In this guidance, CMS is acknowledging that the use of step therapy is a recognized utilization management tool. The allowance of step therapy practices for Part B drugs will help achieve the goal of lower drug prices while maintaining access to covered services and drugs for beneficiaries.

As a result of this recent change, effective July 1st, 2020 we will require review of some Part B drugs for step therapy requirements. These new Step therapy prior authorization requirements will not apply to members who are currently and actively receiving medications (members with a paid claim within the past 365 days) on the list. This will only apply to members that are “new” to the drug(s) listed below.

For dates of service on or after July 1st, 2020 we will require step therapy prior authorization for the following Part B medications:

Step Therapy Drug Class Drug Name HCPCS
Blood Modifier Agent/Colony Stimulating Factors Neulasta J2505

Refer to for additional information

Web Content Viewer - Fixed Context

Updated October 1, 2020